Replicor发表后续研究，以扩展其对REP 2139的机械理解

StephenW

Replicor publishes follow-on study expanding its mechanistic understanding of REP 2139

MONTREAL, June 23rd, 2020 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, announces the publication of an expanded in vitro study of the antiviral effects of REP 2139 in HBV entitled “Characterization of the antiviral effects of REP 2139 on the HBV lifecycle in vitro” in the journal Antiviral Research.

https://www.sciencedirect.com/sc ... i/S0166354220302679

Replicor’s ongoing collaboration with Dr. Patrick Labonté at the Institute Armand Frappier, (IAF-INRS, Laval, Quebec, Canada) has the overall goal of identifying the antiviral and molecular mechanisms of NAPs.

This latest publication established the following:

1.      The specific inhibition of the assembly / secretion of HBV subviral particles with little to no impact on secretion of HBeAg or Dane particles.

2.      The identification of previously characterized, constitutive HBsAg proteolytic mechanisms driving the reduction in intracellular HBsAg observed in the presence of NAPs.

3.      Little to no effect on the transcription / translation of viral RNAs, DNA or proteins by NAPs.

Dr. Andrew Vaillant, CSO at Replicor commented, “The in vitro investigation of NAPs is complicated by the absence of intracellular trafficking normally occurring in vivo.  Early independent investigations demonstrated numerous in vitro artifacts (verified by in vivo and human efficacy data) with transfection (including RNAiMax) demonstrating the unsuitability of this approach for evaluating the antiviral mechanisms of NAPs or their efficacy in vitro.  This necessitated the development of a novel in vitro system (described in our previous publication) which both restored normal intracellular trafficking of NAPs in vitro and produced results consistent with in vivo and human efficacy data with a wide variety of differentially modified NAPs.  This second publication from Dr. Labonté’s lab uses this same model system to establish the specific and selective effect of NAPs on the assembly and secretion of HBV SVP and is currently being used to identify host target(s) of NAPs involved in the assembly / secretion of HBV SVPs”.

A detailed summary of the issues with evaluating the mechanism and efficacy of NAPs in vitro with transfection can be found here.

About Replicor

Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com.

StephenW

Replicor发表后续研究，以扩展其对REP 2139的机械理解

蒙特利尔，2020年6月23日– Replicor Inc.是一家私有生物制药公司，致力于治疗慢性乙型肝炎病毒（HBV）和慢性HBV和丙型肝炎三角洲病毒（HDV）合并感染的患者，该公司宣布扩大REP 2139在HBV中的抗病毒作用的体外研究，名为“ REP 2139在体外对HBV生命周期的抗病毒作用的表征”。

https://www.sciencedirect.com/sc ... i/S0166354220302679

Replicor与Armand Frappier研究所（IAF-INRS，加拿大魁北克省拉瓦尔）的PatrickLabonté博士正在进行的合作，其总体目标是确定NAP的抗病毒和分子机制。

最新出版物确定了以下内容：

1.特异性抑制HBV亚病毒颗粒的装配/分泌，几乎不影响HBeAg或Dane颗粒的分泌。

2.鉴定先前表征的，构成性HBsAg的蛋白水解机制，以驱动在NAP存在下观察到的细胞内HBsAg降低。

3. NAP对病毒RNA，DNA或蛋白质的转录/翻译几乎没有影响。

Replicor的CSO Andrew Vaillant博士评论说：“由于缺乏通常在体内发生的细胞内运输，因此NAP的体外研究变得复杂。早期的独立研究表明，大量转染（包括RNAiMax）的体外伪像（已通过体内和人类功效数据验证）证明了该方法不适用于评估NAP的抗病毒机制或其体外功效。这就需要开发新的体外系统（在我们先前的出版物中有所描述），该系统既可以恢复正常NAP的细胞内运输，又可以产生与体内和人类功效数据一致的结果，并具有多种差异修饰的NAP。 Labonté博士实验室的第二本出版物使用相同的模型系统来确定NAP对HBV SVP组装和分泌的特异性和选择性作用，目前正用于鉴定参与组装/分泌的NAP的宿主靶标HBV SVP”。

可在此处找到有关评估带有转染的NAP的机制和功效的问题的详细摘要。

关于复制品

Replicor是一家私有生物制药公司，在开发HBV和HDV的治疗方法方面拥有最先进的动物和人类临床数据。该公司致力于加快针对HBV和HBV / HDV合并感染患者的有效治疗方法的开发。有关Replicor的更多信息，请访问我们的网站www.replicor.com。